Acid blockers stop the absorption of all minerals, iron and vitamin B12, so nothing that is eaten benefits the body, the immune system stops working, and hair falls out.
Original statement
انا في ادويه منعتها قبل ما تقبلني اصلا قلتلك تمنعها نهائي من حياتك ادويه مثبطات الحموضه اللي انتوا كنتوا بتشوهات دي اللي هي بتاخدها الصبح قبل الفطار عشان بعد كده كل اللي يخش جسمك انت مش مستفاد بيه بعد كده اللي يخش جسمك كله مش هيلاقي جهاز مناعه شغال بعد كده كل الحديد اللي انت بتاخديه كل فيتامين بي 12 اللي بتاخديه مش هيمتس ما كنتش عارفين ليه ما كنتش عارفين شعركم بيقع عليه وانتم بتاخدوا الكنترلوك او النكس يا ما كنتش عارفين ان مثبطات الحموضه دي بتمنع امتصاص كل المعادن اصلا
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Acid blockers stop the absorption of all minerals, iron and vitamin B12, so nothing that is eaten benefits the body, the immune system stops working, and hair falls out.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الادوية دورها انها تلحقك مش دورها انك تعيش عليها (Open source)
- Published
- 2 April 2024
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Machine-generated or CC transcript of a live stream; wording may contain transcription errors; context is conversational.
- Claimed mechanism
Gastric acid is required for absorption of all nutrients.
- Claimed health effect
Total malabsorption, immune failure, hair loss.
- Population concerned
All PPI users.
- Geographic restriction by Elawady
none found
Diverging source versions
أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/acid-blockers/
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
PPIs block absorption of all minerals and of everything eaten; immunity fails; hair falls out.
2. What is demonstrably correct?
Acid suppression can reduce absorption of vitamin B12 bound to food and has been associated with low magnesium (see C-PPI-03).
3. What is wrong or exaggerated?
'All minerals' and 'nothing you eat benefits you' are false: protein, fat and carbohydrate digestion and most micronutrient absorption continue, mainly in the small intestine with pancreatic enzymes. No evidence was found that PPIs make the immune system stop working or cause hair loss in general.
4. What remains unclear?
The size of effects on iron and calcium absorption in long-term users is less certain.
5. Which studies support it?
Partial support from A-PPI-09 and A-PPI-10 (B12, magnesium only).
6. Which studies contradict it?
COMPASS RCT (I-PPI-01): no excess of serious adverse events other than enteric infections over 3 years.
7. What applies to Germany and Europe?
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
8. What is known about Egypt?
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
9. What practical conclusion is appropriate?
Nutrient-specific monitoring in long-term users is reasonable; the global statement is an exaggeration.
Assessment details
- Rationale for certainty of evidence
Physiology and the observational data show partial, nutrient-specific effects (B12, magnesium, possibly iron and calcium) after long use, not global malabsorption. COMPASS (3 years, ~8,800 on pantoprazole) found no excess of major adverse outcomes except enteric infections.
- Source quality
Video statement without evidence offered; machine transcript.
- Regional transferability
Not region-specific.
- Individual exceptions
Some individuals (e.g. atrophic gastritis, post-surgery, elderly) are more vulnerable to B12 or iron deficiency.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: Do acid blockers stop the absorption of all minerals, iron and B12 so that nothing eaten benefits the body, the immune system stops working and hair falls out?
Research question in detail (PECO)
- Population
- PPI users
- Intervention or exposure
- PPI use
- Comparison
- Non-use
- Geographic scope
- universal pharmacology
- Outcomes
- Absorption of macronutrients and minerals
- Immune function
- Hair loss
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Long-term acid blockers linked to iron deficiency
Lam JR et al.. Gastroenterology 2017 · PMID 27890768 · DOI 10.1053/j.gastro.2016.11.023 Case-control studyabstract checkednewly addedLong-term PPI use is associated with iron deficiency.
- Actual result
- OR 2.49 (2.35-2.64)
- Methodological quality
- moderate
- Relevance
- partial (iron only)
- Limitations
- Observational
What speaks against the claim?
Pantoprazole safety in a large randomised trial
Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056 Randomised controlled trialfull text, structured risk-of-bias assessmentCOMPASS RCT: no excess of serious adverse outcomes other than enteric infections over 3 years.
- Actual result
- As in packet
- Methodological quality
- high
- Relevance
- direct against global malabsorption
- Limitations
- 3 years
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
PPIs affect a few nutrients (B12, magnesium, iron), not absorption in general; no evidence of immune failure or hair loss.
Why some studies weigh more
RCT safety data and physiology outweigh the sweeping claim.
Is a causal relationship established? Not established Only nutrient-specific effects are supported.
Remaining uncertainty
Iron/calcium effect size.
Justified conclusion
Exaggerated.
Does this depend on the country?
- General biological effects
- Pharmacology of PPIs is the same in Egypt and Europe.
- Eating habits
- Not decisive.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant (except ranitidine NDMA impurities, C-PPI-08).
- National production conditions
- Generic products are used in both regions; no evidence of different pharmacological effects.
- Legal rules
- PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
- Actual monitoring data
- No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Share of iron deficiency attributable – Only 3.0% of cases had >=2 y PPI exposure recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Global malabsorption with PPIs
- Starting level
- high (randomised trials)
- Reasons for downgrading
- indirectness
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | TITLE:("proton pump inhibitor*" OR "acid suppress*") AND TITLE:(hypomagnes* OR magnesium OR "vitamin B12" OR cobalamin OR "iron deficiency") AND ("meta-analysis" OR "systematic review") | both directions | 13 | |
| Europe PMC | 26 October 2026 | AUTH:"Lam JR" AND TITLE:"iron deficiency" | supporting evidence | 1 |
Open questions
None.
How deeply was this checked?
4 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 3 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly false (moderate)
Iron data support the partial element already acknowledged.
New sources: I-PPI-116
In plain language
Acid blockers can lower the uptake of some nutrients, mainly vitamin B12 and magnesium, after long use. They do not stop the body from using food in general. Most digestion and absorption happens in the small intestine and continues normally. There is no good evidence that they switch off the immune system or make hair fall out.
Studies on this claim
Studies supporting the claim (2)
-
Acid blockers and low vitamin B12
Lam JR et al.. JAMA 2013 · PMID 24327038 · DOI 10.1001/jama.2013.280490Case-control studycited by the Tayebat archiveabstract checked★ key studyTwo or more years of PPI supply was associated with 65% higher odds of B12 deficiency.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
B12 deficiency association.
- How was the study done?
Case-control in a health system.
- How many people, animals or samples were studied?
210,155 patients.
- What was actually found?
Higher odds with PPI and H2RA.
- How large was the observed effect?
OR 1.65 / 1.25.
- What do the results mean in everyday life?
Long-term users may need B12 checks if symptoms.
- What are the study's limitations?
Detection bias.
- What does it say about Elawady's specific claim?
Supports C-PPI-03.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Exact causal size.
-
PPIs and low magnesium (Rotterdam)
Kieboom BC et al.. Am J Kidney Dis 2015 · PMID 26123862 · DOI 10.1053/j.ajkd.2015.05.012Cross-sectional studycited by the Tayebat archiveabstract checkedPPI users had twice the odds of low magnesium, especially with long use and loop diuretics.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Mg and PPIs.
- How was the study done?
Population cohort.
- How many people, animals or samples were studied?
9,818.
- What was actually found?
Higher odds of low Mg.
- How large was the observed effect?
OR 2.00.
- What do the results mean in everyday life?
Check Mg with diuretics.
- What are the study's limitations?
Single measurement.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Dutch data.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Studies contradicting or limiting the claim (1)
-
Pantoprazole safety in a large randomised trial
Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056Randomised controlled trialindependent cross-checkfull text, structured risk-of-bias assessment★ key studyOver three years, only gut infections were more common with pantoprazole (1.4% vs 1.0%).
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test PPI harms in an RCT.
- How was the study done?
Placebo-controlled trial.
- How many people, animals or samples were studied?
17,598 heart/vascular patients.
- What was actually found?
No excess harm except enteric infections.
- How large was the observed effect?
OR 1.33 enteric infections.
- What do the results mean in everyday life?
PPIs are largely safe for 3 years.
- What are the study's limitations?
3-year duration; specific population.
- What does it say about Elawady's specific claim?
Contradicts most broad harm claims; supports infection risk.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Very long-term effects.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Long-term acid blockers linked to iron deficiency
Lam JR et al.. Gastroenterology 2017 · PMID 27890768 · DOI 10.1053/j.gastro.2016.11.023Case-control studyindependent cross-checkabstract checked★ key studyPeople who took PPIs for 2 years or more had about 2.5 times the odds of iron deficiency, more with higher doses.
Supports iron effect, not global malabsorption
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Check acid suppression and iron deficiency.
- How was the study done?
Case-control study.
- How many people, animals or samples were studied?
77,046 cases, 389,314 controls.
- What was actually found?
OR 2.49 for >=2 y PPI; dose-response; reversible.
- How large was the observed effect?
2.49 (2.35-2.64).
- What do the results mean in everyday life?
Long-term users may need iron checked if symptomatic.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Supports nutrient-specific effects, not 'nothing is absorbed'.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot prove causation in every user.
No study in this group is marked as key.
Regional context
Germany / EU
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
Egypt
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
What applies in my country?
General scientific assessment
Mostly false Exaggerated: PPIs affect a few nutrients, not the absorption of everything.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.. Lam JR et al.. JAMA 2013 · PMID 24327038 · DOI 10.1001/jama.2013.280490
- Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.. Kieboom BC et al.. Am J Kidney Dis 2015 · PMID 26123862 · DOI 10.1053/j.ajkd.2015.05.012
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
- Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.. Lam JR et al.. Gastroenterology 2017 · PMID 27890768 · DOI 10.1053/j.gastro.2016.11.023